Patents by Inventor Francesca D'Addio

Francesca D'Addio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TMEM219 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20230242649
    Abstract: The present invention relates to antibodies or antigen binding fragments thereof that bind specifically to the IGFBP3 receptor, namely TMEM219, to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 16, 2020
    Publication date: August 3, 2023
    Inventors: Paolo FIORINA, Giovanni AMABILE, Francesca D'ADDIO
  • IGFBP3 ANTIBODIES AND THERAPEUTIC USES THEREOF
    Publication number: 20230039165
    Abstract: The present invention relates to antibodies or antigen binding fragment thereof that binds specifically to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 9, 2023
    Inventors: Giovanni AMABILE, Paolo FIORINA, Francesca D'ADDIO
  • ANTIBODIES AND USES THEREOF
    Publication number: 20210388072
    Abstract: The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP3 and does not displace the binding of IGF-I to IGFBP3. The antibody inhibits or reduces the binding of IGFBP3 to the TMEM219 receptor. The invention also relates to methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: October 2, 2019
    Publication date: December 16, 2021
    Inventors: Paolo FIORINA, Francesca D'ADDIO, Francesca ZAGARI
  • Inhibitor of IGFBP3/TMEM219 Axis and Diabetes
    Publication number: 20210169973
    Abstract: The present invention relates to the role of the IGFBP3/TMEM219 axis in the onset of diabetes and the related use of IGFBP3/TMEM219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing Type 1 and/or Type 2 diabetes and relative kit.
    Type: Application
    Filed: February 12, 2021
    Publication date: June 10, 2021
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Inhibitor of IGFBP3/TMEM219 axis and diabetes
    Patent number: 11020453
    Abstract: The present invention relates to the role of the IGFBP3/TMEM219 axis in the onset of diabetes and the related use of IGFBP3/TMEM219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing Type 1 and/or Type 2 diabetes and relative kit.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: June 1, 2021
    Assignee: Ospedale San Raffaele Srl
    Inventors: Francesca D'Addio, Paolo Fiorina
  • INHIBITORS OF IGFBP3 BINDING TO TMEM219 FOR TREATMENT OF INTESTINAL DISEASES
    Publication number: 20200316168
    Abstract: The present invention relates to an inhibitor of IGFBP3 binding to TMEM219 and uses thereof for the treatment and/or prevention of an intestinal disease in a subject, in particular the treatment and/or prevention of diabetic enteropathy or inflammatory bowel disease.
    Type: Application
    Filed: April 22, 2020
    Publication date: October 8, 2020
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases
    Patent number: 10682391
    Abstract: The present invention relates to an inhibitor of IGFBP3 binding to TMEM219 and uses thereof for the treatment and/or prevention of an intestinal disease in a subject, in particular the treatment and/or prevention of diabetic enteropathy or inflammatory bowel disease.
    Type: Grant
    Filed: June 6, 2016
    Date of Patent: June 16, 2020
    Assignee: Ospedale San Raffaele SRL
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Inhibitor of IGFBP3/TMEM219 Axis and Diabetes
    Publication number: 20180243367
    Abstract: The present invention relates to the role of the IGFBP3/TMEM219 axis in the onset of diabetes and the related use of IGFBP3/TMEM219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing Type 1 and/or Type 2 diabetes and relative kit.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 30, 2018
    Inventors: Francesca D'Addio, Paolo Fiorina
  • Inhibitor of IGFBP3/TMEM219 Axis and Diabetes
    Publication number: 20180169184
    Abstract: The present invention relates to the role of the IGFBP3/TMEM219 axis in the onset of diabetes and the related use of IGFBP3/TMEM219 axis inhibitors for the treatment and/or prevention of diabetes. The invention also relates to a method to identify a subject at risk of developing Type 1 and/or Type 2 diabetes and relative kit.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 21, 2018
    Inventors: Francesca D'Addio, Paolo Fiorina
  • IGFBP3 AND USES THEREOF
    Publication number: 20180172708
    Abstract: The present invention relates to an inhibitor of IGFBP3 and uses thereof for the treatment and/or prevention of an intestinal disease, in particular of diabetic enteropathy or inflammatory bowel disease. The present invention also relates to IGFBP3 and uses thereof for the diagnosis, prognosis or an intestinal disease, in particular of diabetic enteropathy or inflammatory bowel disease.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 21, 2018
    Inventors: Francesca D'Addio, Paolo Fiorina